TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Wednesday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

TXMD opened at $1.41 on Wednesday. The firm has a 50 day moving average of $1.55 and a two-hundred day moving average of $1.75. TherapeuticsMD has a 12-month low of $1.15 and a 12-month high of $2.99.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP grew its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.